BIRC5 and prostate carcinoma: Ewe et al. [54], using the same phenomenon that is RNA interference but a different molecular target (survivin, an apoptosis inhibitor [114]), reduced PC-3 (prostate cancer) cell proliferation in a murine xenograft model, while observing a lack of immunostimulation upon systemic administration of DPPC-based lipopolyplexes.